Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 1, 2001 - Issue 1
Submit an article Journal homepage
90
Views
25
CrossRef citations to date
0
Altmetric
Review

Use of acetylcholinesterase inhibitors in Alzheimer’s disease

Shehram Moghul Memory Assessment and Research Centre,Moorgreen Hospital, Botley Road,Southampton, SO30 3JB, UK. [email protected]
&
David Wilkinson Memory Assessment and Research Centre,Moorgreen Hospital, Botley Road,Southampton, SO30 3JB, UK. [email protected]
Pages 61-69 | Published online: 10 Jan 2014

References

  • Rogers SL, Doody RS, Mobs RC, Friedhoff LT and the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer's Disease. At& Intern. Med.158,1021–1031 (1998).
  • Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's Disease. Lancet. 2, 1403 (1976).
  • Bartus BT, Dean RL, Beer B. The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408–417 (1982).
  • Wilkinson D. Drugs for the treatment of Alzheimer's Disease. IJCP56(2), 129–134 (2001).
  • Holmes C, Wilkinson D. Molecular biology of Alzheimer's Disease. Advances in Psychiatric Treatment6, 193–200 (2000).
  • Farlow M, Gracon SI, Hershey LA, Lewis KW Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in AD. The Tacrine Study Group. JAIVIA 268(18), 2523–2529 (1992).
  • Knapp MJ, Knopman DS, Soloman PR et al A 30 week randomized controlled trial of high dose tacrine in patients with AD. JAIVIA 271(13), 985–991 (1994).
  • Antuono PG. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group. Arch. Intern. 114ed. 155, 1766–1772 (1995).
  • Canal I, Imbimbo BR Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Gun. Pharmacol Ther. 60,218–228 (1996).
  • De Jongh P Clinical development of metrifonate: an overview of cognitive and global outcomes. In: Collegium Internationale PTchopharmocologium. Glasgow, UK: Bayer AG (1998). iiRoger SL, Doody RS, Mohs RC et al. Donepezil improves cognition and global function in Alzheimer's disease. A 15 week, double-blind, placebo-controlled study. Arch. Int. .114ed. 158, 1021–1031 (1998).
  • Rogers SL, Farlow MR, Doody RS et al A 24 week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology50,136–145 (1998).
  • Burns A, Rossor M, Hecker eta]. The effects of donepezil in Alzheimer's disease-results from a multinational trial. Dement. Geriatr Cogn. Disord 10,237–244 (1999).
  • Corey-Bloom J, Anand R, Veach J. A randomised trial evaluating the efficacy and safety of ENA 173 (rivastigmine tartate) a new acetylcholinesterase inhibitor, in patients with mild-to-moderately severe Alzheimer's disease. Int. J. Genetic fiychopharmacol 1,55–65 (1998).
  • Rosler M, Anand R, Cicin-Sain A et al Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ318,633–640 (1999).
  • Wilkinson D, Murray J. Galantamine: A randomized double-blind, dose-finding trial in patients with Alzheimer's disease. kit Geriatr. Psych. 2001 (In Press).
  • Raskind MA, Peskind ER Galantamine in Alzheimer's disease: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology54(12), 2261–2268 (2000).
  • Wilcock GK, Lilienfield S, Gaen E. Efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicentre, randomised controlled trial. Galantamine International-1 Study Group. BM J321(727 4), 1445–1449 (2000).
  • Summers WK, Majovski LV, Marsh GM et al Oral tetrahydroaminoacridiine in long-term treatment of senile dementia, Alzheimer type. N. Engl Med 314, 1241–1245 (1986).
  • •This study proved to be the catalyst for further work using AChE-Is in AD.
  • Knapp MJ, Knopman DS, Soloman PR et al A 30 week randomized controlled trial of high dose tacrine in patients with AD. JAIVIA 271(13), 985–991 (1994).
  • Watkins PB, Zimmerman JH, Knapp MJ, Grazon SI, Lewis KW Hepatotoxic effects of tacrine administration in patients with Alzheimer's Disease. JAIVIA 271(13), 992–998 (1994).
  • Davis KL, Thal LT, Gamzu ER et al A double-blind, placebo-controlled, multi-center study of tacrine for Alzheimer's Disease. N Engl. Med. 327(18), 1253–1259 (1992).
  • Qizilbash N, Whitehead A, Higgis J, Wilcock G, Schneider L, Farlow M. The Dementia Trialists' Collaboration. Cholinesterase Inhibition for AD. JAIVIA 280(20), 1777–1782 (1998).
  • Becker RE, Collier JA, Markwell SJ eta]. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer's Disease. Alzheimer Dis. Assoc asonl. 10,124–131 (1996).
  • Cummings JL, Cyrus PA, Bieber F et al Metrifonate treatment of the cognitive deficits of Alzheimer's Disease. Neumlogy 50,1214–1221 (1998).
  • Morris JC, Cyrus PA, Orazem et al Metrifonate benefits cognitive, behavioral and global function in patients with Alzheimer's Disease. Neumlogy50, 1222–1230 (1998).
  • Dubois B, McKeith I, Ogogozo JM eta]. A multi-center, randomised, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's Disease : the MALT study. Int.j Geriatr PTchiatry14,973–982 (1999).
  • Shikiar R, Shakespeare A, Sagnier PP eta]. The impact of metrifonate therapy on caregivers of patients with AD: results from the MALT clinical trial. jAm. Geriatr Soc. 48,268-274 (2000).
  • Wilkinson D. The pharmacology of donepezil: a new treatment for Alzheimer's Disease. Exp. Opin. Pharmacother.1(1), 121–135 (1999).
  • Birk JS, Melzer D, Beppy H. Donepezil for mild and moderate Alzheimer's Disease (Cochrane Review). In: The Cochrane Library (Issue 2). Oxford: Update Software, UK (2001).
  • •A comprehensive, systematic review of trials using donepezil in AD.
  • The ICD-10 Classification of Mental and Behavioral Disorders. Clinical descriptions and diagnostic guidelines. World Health Organisation, Geneva, Switzerland (1992).
  • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 4,939–944 (1984).
  • •Standard diagnostic criteria used to diagnose AD in drug trials.
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorsers. 3rd revised edition. Washington DC, USA: APA, (1987).
  • Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's Disease. Am J. Psychiat. 141,1356–1364 (1984).
  • ••This paper contains the originaldescription of the ADAS-cog, which is now the standard test of cognition in drug trials in AD.
  • Schneider LS, Olin JT, Doody RS et al Validity and reliability of the Alzheimer's Disease Co-operative Study - Clinical Global Impression of Change. AD Assoc. Dis. 11 (Suppl. 2), S22-32 (1997).
  • Winblad B, Engedal K, Soininen H etal. Donepezil enhances global function, cognition and activities if daily living compared with placebo in a one-year, double-blind trial in patients with mild-to-moderate Alzheimer's disease. Aiumlogy57, 489–496 (2001).
  • Livingston G, Katona C. How useful are cholinesterase inhibitors in the treatment of Alzheimer's Disease? A number needed to treat analysis. Int. J. Ceriatr fiychiatry15, 203–207 (2000).
  • •A clinically meaningful way of summarizing evidence regarding use of AChE-Is in AD.
  • Cook RJ, Sackett DC. The number needed to treat: a clinically useful measure of treatment effect. BMJ310, 452–454 (1995).
  • Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's Disease (Cochrane Review). In: The Cochrane Library (Issue 2). Oxford: Update Software, UK (2001).
  • •A systematic review of the evidence from robust clinical trials regarding rivastigmine.
  • Wilkinson D, Passmore P, Potocnik F, Maud C, Hock C. Donepezil compared with rivastigmine in Alzheimer's dosease: similar efficacy but better tolerability and physician and caregiver satisfaction in a multinational randomized trial. Poster, American Assoc Geriatric Psychiatry San Francisco, USA (2001).
  • Olin J, Schneider L. Galantamine for Alzheimer's Disease (Cochrane Review). In: The Cochrane Library (Issue 2). Oxford: Update Software, UK (2001).
  • •A recently up-dated systematic review summarizing the evidence regarding galantamine from RCTs in AD.
  • O'Brien JT, Ballard CG. Drugs for Alzheimer's disease. BM J323, 123–124 (2001).
  • Clipp EC, Moore MJ. Caregiver time use: An outcome measure in clinical trial research on Alzheimer's Disease. Clin. Pharmacol Ther. 58, 228–236 (1995).
  • Shikiar R, Shakespeare A, Sagnier PP et al The impact of metrifonate therapy on caregivers' of patients with Alzheimer's Disease: results from the MALT clinical trial. Am. Ceriatr Soc. 48, 268–274 (2000).
  • Gauthier S, Lussier land the TriAD Study Group. An open-label trial to assess the effectiveness of donepezil treatment on caregiver burden in Alzheimer's disease - an interim report. Poster presentation.
  • Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffers DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Lache County Study of Memory in Ageing. Am. J. Psychiatry157,708–714 (2000).
  • Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44, 2308–2314 (1994).
  • Cummings JL, Kauper D. Neuropsychiatric aspects of Alzheimer's Disease: the Cholinergic hypothesis revisited. Neumlogy 47, 876–883 (1996).
  • Tariot PN, Solomon PR, Morris JC, Kershaw P, Lillenfield S, Ding C and the Galantamine USA-10 Study Group 2000. A 5 month, randomized, placebo-controlled trial of galantamine in Alzheimer's Disease. Neurology 54, 2269–2276 (2000).
  • Gelder M, Mayou R, Geddes J. In: Psychiatry (2nd edition). Oxford University Press, UK. 317 (1999).
  • Davis KL, Thal LJ, Gamzu ER eta]. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. NEngI.j Merl 327(18), 1253–1259 (1992).
  • Mohs R, Doody R, Morris et al A 1-year placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57, 481–488 (2001).
  • Galasko D, Edland SD, Morris JC, Clark C, Mohs R, Koss E. The consortium to establish a registry for Alzheimer's disease (CERAM Part XI. Clinical milestones in patients with Alzheimer's disease. Neurology 45,1451–1455 (1995).
  • Holmes C, Cairns N, Lantos P eta]. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy Bodies. BE J. Psych. 174, 45–50 (1999).
  • Erkinjuntti T, Lilienfield S. Galantamine shows efficacy in patients with Alzheimer's Disease with cerebrovascular or probable vascular dementia. Poster presented at the 53rd Annual Meeting of the American Academy of Neurology, Philadelphia, PA, USA, May 2001.
  • McKeith I, Del Ser T, Spano P et al Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356(9247), 2031–2036.
  • Lanctot KL, Hermann N. Donepezil for behavioral disorders associated with Lewy bodies: a case series. Int. J. Cellar. Psychiatry 15, 338–345 (2000).
  • Ernst RL, Hay JVV The US economic and social costs of Alzheimer's Disease revisited. Am.Public Health. 84, 1261–1264 (1994)in Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer's Disease. Clinical Therapeutics. 20(4), 838–850 (1998).
  • Knopman D, Schneider L, Davis K eta]. Long-term tacrine (Cognex°) treatment: Effects on nursing home placement and mortality. Neurology 47, 166–177 (1996).
  • Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin. Ther. 20(4), 838–850 (1998).
  • Knapp M, Wilkinson D, Wigglesworth R The economic consequences of Alzheimer's disease in the context of new drug developments. Int. J. Ceriatr Psychiatry 13(8), 531–543 (1998).
  • •An overview of the potential pharmacoeconomic consequences of widespread AChE-I use.
  • Wilkinson D, Schwalen S. Reminyl (Galantamine) produces significant improvement in patients with 'advanced moderate' dementia. Poster presented at the International Psychogeriatric Association, Nice, France. Sept, 2001.
  • Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E and the donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate-to-severe Alzheimer's disease. Neumlogy57(4), 613–621 (2001).

Websites

  • Cummings J, Anand R, Koumaras B, Hartman R. Rivastigmine provides behavioral benefits to Alzheimer's disease patients residing in a nursing home: findings from a 26-week trial. Neurology 54\(Suppl. 3) Abstract (2000). Websites tot www.nice.org.uk. Technology Appraisal Guidance No. 19. Guidance on the Use of Donepezil, Rivastigmine and Galantamine for the treatment of Alzheimer's Disease. (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.